SS Innovations International, Inc. (NASDAQ: SSII) has achieved a significant milestone by surpassing 100 installations of its SSI Mantra surgical robotic system in India and six other countries. The company has reported that over 5,000 surgical procedures have been successfully performed using the SSI Mantra, including 240 cardiac surgeries and 32 telesurgeries. This marks a substantial increase from the 2,759 robotic surgeries, including 151 cardiac surgeries and 9 telesurgeries, reported as of December 31, 2024.
Dr. Sudhir Srivastava, the Chairman of the Board and Chief Executive Officer of SS Innovations, expressed enthusiasm about the milestone, attributing the growing demand and acceptance of the SSI Mantra to its premium quality, innovative features, ease of use, improved patient experience, and overall cost-effectiveness. The company aims to democratize access to cutting edge robotic surgery by deploying the SSI Mantra in existing markets and pursuing new geographies. Additionally, SS Innovations plans to submit a de novo application for approval to market the SSI Mantra to the U.S. Food and Drug Administration by the end of July 2025 and pursue a European Union CE marking certification by late 2025.
SS Innovations International, Inc. is an American company headquartered in India that specializes in developing innovative surgical robotic technologies, including the SSI Mantra surgical robotic system and the SSI Mudra surgical instruments. The company's vision is to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population.
The company's achievement in surpassing the 100-installation milestone and the notable increase in the number of surgical procedures performed using the SSI Mantra demonstrate the growing adoption and impact of its robotic surgical technologies. The market has reacted to these announcements by moving the company's shares 12.0% to a price of $5.32. Check out the company's full 8-K submission here.
